`Date Filed: February 28, 2020
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`MYLAN LABORATORIES LTD,
`Petitioner
`
`v.
`
`JANSSEN PHARMACEUTICA NV,
`Patent Owner.
`
`________________
`
`Case IPR2020-00440
`Patent 9,439,906
`
`________________
`
`
`JANSSEN PHARMACEUTICA NV’S MANDATORY NOTICES
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2020-00440
`U.S. Patent 9,439,906
`
`
`Patent Owner Janssen Pharmaceutica NV submits the following mandatory
`
`disclosures pursuant to 37 C.F.R. § 42.8:
`
`REAL PARTY-IN-INTEREST
`
`Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc., which are
`
`wholly-owned subsidiaries of Johnson & Johnson (“J&J”), are real parties-in-
`
`interest. J&J, a publicly held company, is also a real party-in-interest.
`
`RELATED MATTERS
`
`United States Patent Number 9,439,906 (the “’906 Patent”) is at issue in the
`
`following district court actions: Janssen Pharmaceuticals, Inc. et al. v. Teva
`
`Pharmaceuticals USA, Inc. et al., 2:18-cv-00734 (D.N.J.); Janssen
`
`Pharmaceuticals, Inc. et al. v. Mylan Laboratories Ltd., 2:19-cv-16484 (D.N.J.);
`
`Janssen Pharmaceuticals, Inc. et al. v. Pharmascience Inc. et al., 2:19-cv-21590
`
`(D.N.J.); Janssen Pharmaceuticals, Inc. et al. v. Pharmascience Inc. et al., 1:19-
`
`cv-02313 (D. Del.). The ’906 Patent was also at issue in Janssen Pharmaceuticals,
`
`Inc. et al. v. Mylan Laboratories Ltd. et al., 1:19-cv-00153 (N.D. W. Va.) and
`
`Janssen Pharmaceuticals, Inc. et al. v. Mylan Laboratories Ltd., 1:19-cv-01488 (D.
`
`Del.), which are now dismissed.
`
`
`
`1
`
`
`
`
`LEAD AND BACKUP COUNSEL / SERVICE INFORMATION
`
`Lead Counsel
`
`Barbara L. Mullin
`PATTERSON BELKNAP WEBB &
`TYLER LLP
`1133 Avenue of the Americas
`New York, NY 10036
`bmullin@pbwt.com
`Tel.: (212) 336-2468
`Fax: (212) 336-1231
`USPTO Registration No. 38,250
`
`
`
`
`Backup Counsel
`
`
`
`Ruben H. Munoz
`AKIN GUMP STRAUSS HAUER
`& FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`rmunoz@akingump.com
`Tel.: (215) 965-1263
`Fax: (215) 965-1210
`USPTO Registration No. 66,998
`
`Andrew D. Cohen
`PATTERSON BELKNAP WEBB &
`TYLER LLP
`1133 Avenue of the Americas
`New York, NY 10036
`acohen@pbwt.com
`Tel.: (212) 336-2605
`Fax: (212) 336-1231
`USPTO Registration No. 61,508
`
`Joong Youn (Jay) Cho
`PATTERSON BELKNAP WEBB &
`TYLER LLP
`1133 Avenue of the Americas
`New York, NY 10036
`jcho@pbwt.com
`Tel.: (212) 336-2989
`Fax: (212) 336-1231
`USPTO Registration No. 75,052
`
`
`
`
`
`2
`
`
`
`IPR2020-00440
`U.S. Patent 9,439,906
`
`
`Please direct all correspondence to lead counsel and backup counsel at the
`
`contact information above. Patent Owner consents to electronic mail service at the
`
`following email addresses:
`
`bmullin@pbwt.com
`rmunoz@akingump.com
`acohen@pbwt.com
`jcho@pbwt.com
`JanssenInvegaIPR@pbwt.com
`JANS-InvegaIPR@akingump.com
`
`
`Pursuant to 37 C.F.R. § 42.10(b) a Power of Attorney is being filed
`
`concurrently.
`
`Respectfully submitted,
`
`
`
`By: / Barbara L. Mullin /
`Barbara L. Mullin
`Registration No. 38,250
`Counsel for Patent Owner
`
`Date: February 28, 2020
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`IPR2020-00440
`U.S. Patent 9,439,906
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Janssen
`
`Pharmaceutica NV’s Mandatory Notices were served on counsel of record on
`
`February 28, 2020 by filing this document through the End-to-End System, as well
`
`as delivering a copy via electronic mail to counsel of record for the Petitioner at the
`
`following addresses:
`
`Jirwnse Malik – jitty.malik@katten.com
`Guylaine Haché – guylaine.hache@katten.com
`Jillian Schurr – jillian.schurr@katten.com
`Alissa M. Pacchioli – alissa.pacchioli@katten.com
`Lance Soderstrom – lance.soderstrom@katten.com
`
`
`
`Date: February 28, 2020
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Barbara L. Mullin/
`Barbara L. Mullin
`Registration No. 38,250
`Counsel for Patent Owner
`
`4
`
`
`